Giredestrant
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Giredestrant (also known as GDC-9545, RG6171, or RO7197597) is an investigational oral selective estrogen receptor degrader (SERD) developed by Genentech, a member of the Roche Group, for the treatment of estrogen receptor-positive (ER+), HER2-negative advanced breast cancer, as well as endometrial cancer, ovarian cancer, and other solid tumors. It is a potent, nonsteroidal compound that antagonizes estrogen effects by competitively binding to both wild-type and mutant estrogen receptors with nanomolar potency. Giredestrant works by inducing an inactive conformation of the estrogen receptor ligand-binding domain and promoting proteasome-mediated degradation of the receptor protein. As of May 2025, giredestrant is in clinical trials and has received Fast Track designation from the Food and Drug Administration (FDA) for ER+, HER2-negative second- and third-line metastatic breast cancer.
Giredestrant (also known as GDC-9545, RG6171, or RO7197597) is an investigational oral selective estrogen receptor degrader (SERD) developed by Genentech, a member of the Roche Group, for the treatment of estrogen receptor-positive (ER+), HER2-negative advanced breast cancer, as well as endometrial cancer, ovarian cancer, and other solid tumors. It is a potent, nonsteroidal compound that antagonizes estrogen effects by competitively binding to both wild-type and mutant estrogen receptors with nanomolar potency. Giredestrant works by inducing an inactive conformation of the estrogen receptor ligand-binding domain and promoting proteasome-mediated degradation of the receptor protein. As of May 2025, giredestrant is in clinical trials and has received Fast Track designation from the Food and Drug Administration (FDA) for ER+, HER2-negative second- and third-line metastatic breast cancer. acelERA (NCT04576455): A Phase II study compared giredestrant (30 mg oral daily) to physician's choice of endocrine therapy (e.g., fulvestrant, aromatase inhibitors) in patients with 1–2 prior lines of systemic therapy for ER+, HER2-negative advanced breast cancer. At the clinical cutoff (February 18, 2022), the hazard ratio (HR) for progression-free survival (PFS) was 0.81 (95% CI, 0.60–1.10; P = 0.1757), showing no statistically significant improvement. A stronger PFS trend was observed in ESR1-mutated tumors (HR 0.60, 95% CI, 0.35–1.03). pionERA (NCT04478266): A Phase III, randomized, open-label study evaluating giredestrant versus fulvestrant, both combined with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib), in patients with ER+, HER2-negative advanced breast cancer resistant to prior adjuvant endocrine therapy. lidERA (NCT04546002): A Phase III study comparing adjuvant giredestrant to physician's choice of endocrine monotherapy in ER+, HER2-negative early breast cancer. persevERA (NCT04687236): A Phase III study comparing giredestrant plus palbociclib and placebo versus letrozole plus palbociclib and placebo in first-line metastatic ER+, HER2-negative breast cancer. This trial did not show a significant improvement of the giredestrant group over the control group. evERA (NCT05306340): A Phase III trial evaluating giredestrant with everolimus in ER+, HER2-negative advanced breast cancer post-CDK4/6 inhibitors. morpheus (NCT04802759): A Phase I study assessing giredestrant with various combinations, including the immune checkpoint inhibitor atezolizumab, in metastatic breast cancer.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1347515095 under CC BY-SA 4.0; modifications have been made.